Corline Biomedical AB announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was SEK 3.366 million compared to SEK 3.806 million a year ago. Operating loss was SEK 2.141 million compared to SEK 2.575 million a year ago. Net loss was SEK 2.153 million compared to SEK 2.575 million a year ago. Basic loss per share from continuing operations was SEK 0.1 compared to SEK 0.15 a year ago. For the half year, total revenue was SEK 6.129 million compared to SEK 8.100 million a year ago. Operating loss was SEK 3.546 million compared to SEK 5.082 million a year ago. Net loss was SEK 3.558 million compared to SEK 5.082 million a year ago. Basic loss per share from continuing operations was SEK 0.18 compared to SEK 0.3 a year ago.